BCYC241220P22500
- 2.50
- 0.000.00%
Bicycle Therapeutics Newsroom
Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference
Bicycle Therapeutics Initiated at Equal-Weight by Stephens & Co.
Stephens Initiates Bicycle Therapeutics(BCYC.US) With Hold Rating, Announces Target Price $25
Morgan Stanley Initiates Bicycle Therapeutics(BCYC.US) With Hold Rating, Announces Target Price $30
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
Bicycle Therapeutics Plc (NASDAQ:BCYC) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Bicycle Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
JMP Securities Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $32
Barclays Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $40
H.C. Wainwright Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $55
RBC Capital Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $35
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RBC Capital Reiterates Outperform on Bicycle Therapeutics, Maintains $35 Price Target
Bicycle Therapeutics Analyst Ratings
Bicycle Therapeutics | 10-Q: Q3 2024 Earnings Report
Bicycle Therapeutics | 8-K: Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
Express News | Bicycle Therapeutics PLC: Expected Financial Runway Into 2H 2027
Bicycle Therapeutics 3Q Rev $2.68M >BCYC
Press Release: Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
Express News | Bicycle Therapeutics Q3 Basic EPS USD -0.74